Big first scored with nerve diseases.
Lewin
R
R
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D002986:Clinical Trials as Topic; D015198:Designer Drugs; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009474:Neurons / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010627:Phenethylamines / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000378:metabolism; D012642:Selegiline / Q000627:therapeutic use*; D013378:Substantia Nigra / Q000473:pathology / Q000503:physiopathology
D015198:Designer Drugs; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D011725:Pyridines; D012642:Selegiline; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine